Display options
Cite
Möllers T, Stocker H, Perna L, et al. Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease. Alzheimers Dement (Amst). 2021;13(1):e12151doi: 10.1002/dad2.12151.
Möllers, T., Stocker, H., Perna, L., Nabers, A., Rujescu, D., Hartmann, A. M., Holleczek, B., Schöttker, B., Gerwert, K., & Brenner, H. (2021). Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands), 13(1), e12151. https://doi.org/10.1002/dad2.12151
Möllers, Tobias, et al. "Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 13,1 (2021): e12151. doi: https://doi.org/10.1002/dad2.12151
Möllers T, Stocker H, Perna L, Nabers A, Rujescu D, Hartmann AM, Holleczek B, Schöttker B, Gerwert K, Brenner H. Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease. Alzheimers Dement (Amst). 2021 Feb 10;13(1):e12151. doi: 10.1002/dad2.12151. eCollection 2021. PMID: 33614887; PMCID: PMC7875190.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2021 Feb 10;13(1):e12151. doi: 10.1002/dad2.12151. eCollection 2021.

Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)

Tobias Möllers, Hannah Stocker, Laura Perna, Andreas Nabers, Dan Rujescu, Annette M Hartmann, Bernd Holleczek, Ben Schöttker, Klaus Gerwert, Hermann Brenner

Affiliations

  1. Division of Clinical Epidemiology and Aging Research German Cancer Research Center Heidelberg Germany.
  2. Network Aging Research Heidelberg University Heidelberg Germany.
  3. Medical Faculty Heidelberg University Heidelberg Germany.
  4. Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry Munich Germany.
  5. Department of Biophysics Ruhr-University Bochum Bochum Germany.
  6. Department of Biophysics Center for Protein Diagnostics (ProDi) Biospectroscopy Ruhr-University Bochum Bochum Germany.
  7. Psychotherapy and Psychosomatics University Clinic and Outpatient Clinic for Psychiatry Martin-Luther-University Halle-Wittenberg Halle/Saale Germany.
  8. Saarland Cancer Registry Saarbrücken Germany.

PMID: 33614887 PMCID: PMC7875190 DOI: 10.1002/dad2.12151

Abstract

INTRODUCTION: Determining potential risk factors of amyloid beta (Aβ) misfolding in blood, a risk marker for clinical Alzheimer's disease (AD), could have important implications for its utility in future research and clinical settings.

METHODS: Participants aged 50 to 75 years attending a general health examination were recruited for a prospective community-based cohort study in Saarland, Germany, in 2000 to 2002. For these analyses, participants with available Aβ misfolding measurements and clinical AD information at 17-year follow-up were included (

RESULTS: Age did not show any association with Aβ misfolding in plasma; however, a strong association of both age and Aβ misfolding with the incidence of clinical AD was evident. Education and cardiovascular diseases were likewise not associated with Aβ misfolding.

DISCUSSION: Structural measurement of Aβ misfolding in blood plasma is an age-independent risk marker of clinical AD among older adults, supporting that risk of clinical AD is already largely determined before older adulthood.

© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Keywords: Alzheimer's disease; age; amyloid beta misfolding; cohort study; risk factors

Conflict of interest statement

The secondary structure‐based, Aβ misfolding marker measured by the iRS is protected by one approved patent (EP3324187B1) and three patent applications (WO 2015121339 A1, WO 2018091743 A1, and WO 2018

References

  1. JAMA Neurol. 2020 Feb 1;77(2):175-183 - PubMed
  2. Ann Neurol. 2017 Nov;82(5):706-718 - PubMed
  3. Cell Mol Life Sci. 2011 Apr;68(8):1429-38 - PubMed
  4. JAMA Neurol. 2013 May;70(5):600-6 - PubMed
  5. Ann Neurol. 2019 Feb;85(2):272-279 - PubMed
  6. JAMA Neurol. 2018 Sep 1;75(9):1124-1131 - PubMed
  7. Ann Clin Transl Neurol. 2018 Sep 07;5(10):1184-1191 - PubMed
  8. N Engl J Med. 2012 Aug 30;367(9):795-804 - PubMed
  9. Ann Neurol. 2013 Dec;74(6):905-13 - PubMed
  10. JAMA Neurol. 2019 Jul 14;: - PubMed
  11. Brain. 2019 Feb 1;142(2):460-470 - PubMed
  12. Acta Neuropathol. 2018 Jan;135(1):85-93 - PubMed
  13. Alzheimers Dement. 2011 May;7(3):280-92 - PubMed
  14. Alzheimers Dement. 2018 Apr;14(4):535-562 - PubMed
  15. Lancet Neurol. 2012 Nov;11(11):1006-12 - PubMed
  16. EMBO Mol Med. 2018 May;10(5): - PubMed
  17. Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12 - PubMed
  18. Mol Neurobiol. 2012 Apr;45(2):366-78 - PubMed
  19. Ann Neurol. 2018 Jan;83(1):74-83 - PubMed
  20. Acta Neuropathol. 2011 Oct;122(4):401-13 - PubMed
  21. Alzheimers Dement. 2019 Sep;15(9):1149-1159 - PubMed
  22. Front Aging Neurosci. 2018 Aug 21;10:255 - PubMed
  23. Lancet Neurol. 2014 Jun;13(6):614-29 - PubMed
  24. Neurology. 2008 May 6;70(19):1664-71 - PubMed
  25. Anal Chem. 2016 Mar 1;88(5):2755-62 - PubMed
  26. Mol Psychiatry. 2020 May 13;: - PubMed
  27. Dtsch Med Wochenschr. 2004 Dec 3;129(49):2643-7 - PubMed
  28. JAMA. 2017 Apr 11;317(14):1443-1450 - PubMed
  29. Lancet. 2017 Dec 16;390(10113):2673-2734 - PubMed
  30. Alzheimers Dement. 2018 Jul;14(7):858-868 - PubMed
  31. Neurology. 2012 Feb 14;78(7):468-76 - PubMed
  32. PLoS Med. 2017 Mar 21;14(3):e1002258 - PubMed
  33. Acta Neuropathol. 2017 May;133(5):839-856 - PubMed
  34. Am J Epidemiol. 2002 Sep 1;156(5):445-53 - PubMed
  35. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  36. Alzheimers Dement. 2020 Feb;16(2):283-291 - PubMed
  37. JAMA Neurol. 2017 Jun 1;74(6):718-726 - PubMed

Publication Types